Zetagen Therapeutics

www.zetagen.com

Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions. Our multi-patented, ZetaMet™ technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Zetagen exclusively-licensed the platform technology from the State University of New York in 2016. This novel therapy, a drug-eluting implant technology, has successfully passed its preclinical trials and is being prepared for its first human clinical trial in Q4 2021. In addition to ZetaMet™, the Company’s pipeline includes other oncologic treatments for Skeletal Related Events (SREs), i.e., ZetaMet Flowable™ and ancillary osteologic treatments including, ZetaFuse™, ZetaSet™, ZetaDent™ and ZetaBase™. The Company is supported through Series A funding, private and angel investors, and Phase I and Phase II NIH research grants.

Read more

Reach decision makers at Zetagen Therapeutics

Lusha Magic

Free credit every month!

Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions. Our multi-patented, ZetaMet™ technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Zetagen exclusively-licensed the platform technology from the State University of New York in 2016. This novel therapy, a drug-eluting implant technology, has successfully passed its preclinical trials and is being prepared for its first human clinical trial in Q4 2021. In addition to ZetaMet™, the Company’s pipeline includes other oncologic treatments for Skeletal Related Events (SREs), i.e., ZetaMet Flowable™ and ancillary osteologic treatments including, ZetaFuse™, ZetaSet™, ZetaDent™ and ZetaBase™. The Company is supported through Series A funding, private and angel investors, and Phase I and Phase II NIH research grants.

Read more
icon

Country

icon

State

New York

icon

City (Headquarters)

Syracuse

icon

Employees

1-10

icon

Founded

2015

icon

Estimated Revenue

$1 to $1,000,000

icon

Social

  • icon
  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Chief Operating Officer

    Email ****** @****.com
    Phone (***) ****-****
  • Chief Financial Officer

    Email ****** @****.com
    Phone (***) ****-****
  • Board Member

    Email ****** @****.com
    Phone (***) ****-****
  • Chief Executive Officer

    Email ****** @****.com
    Phone (***) ****-****

Technologies

(22)

  • google universal analytics
  • microsoft ajax content delivery network
  • keen io
  • View all (22)

Reach decision makers at Zetagen Therapeutics

Free credits every month!

My account

Sign up now to uncover all the contact details